ONCOVIN Side Effects

5417778-0 | Blood Fibrinogen Decreased, Hyponatraemia, Pancytopenia
on Aug 10, 2007 Female patient from JAPAN , 67 years of age, was diagnosed with chronic myeloid leukaemia and was treated with Oncovin (View Usage). Patient experienced the following unwanted or unexpected effects: blood fibrinogen decreased, hyponatraemia, pancytopenia. Oncovin dosage: Unk, Unk. During the same period patient was treated with GLEEVEC (400 Mg/day) (View Gleevec Review and Gleevec Label ). Patient was hospitalized.

5225278-6 | Blood Fibrinogen Decreased, Hyponatraemia, Pancytopenia
Patient was taking Oncovin (View Usage). Patient had the following side effects: blood fibrinogen decreased, hyponatraemia, pancytopenia on Jan 18, 2007 from JAPAN Additional patient health information: Female patient , 67 years of age, was diagnosed with chronic myeloid leukaemia and. Oncovin dosage: Unk, Unk. During the same period patient was treated with GLEEVEC (400 Mg/day) (View Gleevec Review and Gleevec Label ). Patient was hospitalized.

5198054-0 | Blood Fibrinogen Decreased, Hyponatraemia
Adverse event was reported on Dec 22, 2006 by a Female patient taking Oncovin (View Usage) (Dosage: Unk, Unk) was diagnosed with chronic myeloid leukaemia and. Location: JAPAN , 67 years of age, After Oncovin was administered, patient had the following side effects: blood fibrinogen decreased, hyponatraemia. During the same period patient was treated with GLEEVEC (400 Mg/day) (View Gleevec Review and Gleevec Label ).

4933501-8 | Blood Pressure Systolic Increased, Body Temperature Increased, Confusional State, Cyanosis, Dry Skin, Guillain-barre Syndrome, Haematocrit Decreased, Heart Rate Increased, Loss Of Consciousness
on Feb 20, 2006 Male patient from UNITED STATES , 21 years of age, was diagnosed with non-hodgkin's lymphoma, t-cell lymphoma and was treated with Oncovin (View Usage). Patient experienced the following unwanted or unexpected effects: blood pressure systolic increased, body temperature increased, confusional state, cyanosis, dry skin, guillain-barre syndrome (What is guillain-barre syndrome?), haematocrit decreased, heart rate increased, loss of consciousness. Oncovin dosage: 2 Mg Once It. During the same period patient was treated with CYTOXAN (View Cytoxan Review and Cytoxan Label ), MESNA (View Mesna Review and Mesna Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), COLACE (View Colace Review and Colace Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).


4705334-9 | Blood Lactate Dehydrogenase Increased, Bone Marrow Transplant, Bone Pain, Condition Aggravated, Lymphoma, Pneumocystis Jiroveci Pneumonia, Premature Baby
on Jun 13, 2005 Female patient from , 22 years of age, was diagnosed with lymphoma (What is lymphoma?) and was treated with Oncovin (View Usage). Patient had the following side effects: blood lactate dehydrogenase increased, bone marrow transplant (What is bone marrow transplant?), bone pain, condition aggravated, lymphoma (What is lymphoma?), pneumocystis jiroveci pneumonia, premature baby. Oncovin dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ADRIAMYCIN (DOXORUBICIN /00330901/) (View Adriamycin (doxorubicin /00330901/) Review and Adriamycin (doxorubicin /00330901/) Label ), PREDNISONE (View Prednisone Review and Prednisone Label ).

4704496-7 | Adenocarcinoma, Blood Pressure Increased, Bronchiectasis, Condition Aggravated, Dyspnoea, Hypoxia, Lung Disorder, Malaise
Patient was taking Oncovin (View Usage). After Oncovin was administered, patient had the following side effects: adenocarcinoma, blood pressure increased, bronchiectasis, condition aggravated, dyspnoea, hypoxia, lung disorder, malaise on Jun 13, 2005 from Additional patient health information: Male patient , 60 years of age, weighting 158.7 lb, was diagnosed with lymphoma (What is lymphoma?) and. Oncovin dosage: 2.5 Mg Other. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HYDROCHLORIDE (View Doxorubicin Hydrochloride Review and Doxorubicin Hydrochloride Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

4698477-X | Abdominal Pain Upper, Coagulopathy, Disseminated Intravascular Coagulation, Pancreatitis Acute, Platelet Count Decreased, Tumour Lysis Syndrome
Adverse event was reported on Jun 06, 2005 by a Male patient taking Oncovin (View Usage) (Dosage: 1.5 Mg Other) was diagnosed with acute lymphocytic leukaemia and. Location: , child 7 years of age, weighting 63.93 lb, Patient experienced the following unwanted or unexpected effects: abdominal pain upper, coagulopathy, disseminated intravascular coagulation, pancreatitis acute, platelet count decreased, tumour lysis syndrome. During the same period patient was treated with PINORUBICIN (PIRARUBICIN) (View Pinorubicin (pirarubicin) Review and Pinorubicin (pirarubicin) Label ), DECADRON /CAN/ (DEXAMETHASONE /00016001/) (View Decadron /can/ (dexamethasone /00016001/) Review and Decadron /can/ (dexamethasone /00016001/) Label ), PREDONINE (PREDNISOLONE /00016201/) (View Predonine (prednisolone /00016201/) Review and Predonine (prednisolone /00016201/) Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), POLYMYXIN B SULFATE (View Polymyxin B Sulfate Review and Polymyxin B Sulfate Label ), FUNGIZONE (View Fungizone Review and Fungizone Label ), MEROPEN (MEROPENEM) (View Meropen (meropenem) Review and Meropen (meropenem) Label ), DIFLUCAN (View Diflucan Review and Diflucan Label ). Patient was hospitalized.

4692405-9 | Convulsion, Pneumocystis Jiroveci Pneumonia, Pneumonitis, Thrombosis
on May 26, 2005 Female patient from , 70 years of age, was diagnosed with mixed oligo-astrocytoma and was treated with Oncovin (View Usage). Patient had the following side effects: convulsion, pneumocystis jiroveci pneumonia, pneumonitis, thrombosis. Oncovin dosage: Unk. During the same period patient was treated with NIMUSTINE HYDROCHLORIDE (View Nimustine Hydrochloride Review and Nimustine Hydrochloride Label ), INTERFERON (View Interferon Review and Interferon Label ).

4692345-5 | Disease Recurrence, Histiocytosis Haematophagic, Lymphangitis, Myelodysplastic Syndrome, Pancytopenia
on May 30, 2005 Female patient from , 77 years of age, weighting 158.7 lb, was diagnosed with malignant melanoma and was treated with Oncovin (View Usage). After Oncovin was administered, patient had the following side effects: disease recurrence, histiocytosis haematophagic, lymphangitis, myelodysplastic syndrome, pancytopenia. Oncovin dosage: 1 Mg Other. During the same period patient was treated with DACARBAZINE (View Dacarbazine Review and Dacarbazine Label ), NIDRAN (NIMUSTINE HYDROCHLORIDE) (View Nidran (nimustine Hydrochloride) Review and Nidran (nimustine Hydrochloride) Label ), FERON (INTERFERON BETA) (View Feron (interferon Beta) Review and Feron (interferon Beta) Label ). Patient was hospitalized.

4686991-2 | Disseminated Intravascular Coagulation, Liver Disorder, Neutropenia, Platelet Count Decreased, Venoocclusive Liver Disease
Patient was taking Oncovin (View Usage). Patient experienced the following unwanted or unexpected effects: disseminated intravascular coagulation, liver disorder, neutropenia, platelet count decreased, venoocclusive liver disease on May 24, 2005 from Additional patient health information: Female patient , 71 years of age, weighting 136.7 lb, was diagnosed with acute lymphocytic leukaemia and. Oncovin dosage: 1.4 Mg Other. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DAUNORUBICIN HYDROCHLORIDE (View Daunorubicin Hydrochloride Review and Daunorubicin Hydrochloride Label ), LEUNASE (ASPARAGINASE LEUKAEMIA) (View Leunase (asparaginase Leukaemia) Review and Leunase (asparaginase Leukaemia) Label ), FAMOTIDINE (View Famotidine Review and Famotidine Label ), FIRSTCIN (CEFOZOPRAN HYDROCHLORIDE) (View Firstcin (cefozopran Hydrochloride) Review and Firstcin (cefozopran Hydrochloride) Label ), ISEPACIN (ISEPAMICIN SULFATE) (View Isepacin (isepamicin Sulfate) Review and Isepacin (isepamicin Sulfate) Label ), KYTRIL (View Kytril Review and Kytril Label ), MAXIPIME (View Maxipime Review and Maxipime Label ).

4681975-2 | Myelodysplastic Syndrome
Adverse event was reported on May 18, 2005 by a Female patient taking Oncovin (View Usage) (Dosage: 1 Mg Other) was diagnosed with malignant melanoma and. Location: , 77 years of age, weighting 158.7 lb, Patient had the following side effects: myelodysplastic syndrome. During the same period patient was treated with DACARBAZINE (View Dacarbazine Review and Dacarbazine Label ), NIDRAN (NIMUSTINE HYDROCHLORIDE) (View Nidran (nimustine Hydrochloride) Review and Nidran (nimustine Hydrochloride) Label ), FERON (INTERFERON BETA) (View Feron (interferon Beta) Review and Feron (interferon Beta) Label ).

4674039-5 | Acute Lymphocytic Leukaemia, Aplasia, Blood Glucose Increased, Bronchial Infection, Diabetes Mellitus, Granulocyte Count Decreased, Hepatomegaly, Hypoalbuminaemia, Lung Disorder
on May 05, 2005 Male patient from , 61 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Oncovin (View Usage). After Oncovin was administered, patient had the following side effects: acute lymphocytic leukaemia, aplasia, blood glucose increased, bronchial infection, diabetes mellitus, granulocyte count decreased, hepatomegaly, hypoalbuminaemia, lung disorder. Oncovin dosage: . During the same period patient was treated with CAELYX (DOXORUBICIN HYDROCHLORIDE) (View Caelyx (doxorubicin Hydrochloride) Review and Caelyx (doxorubicin Hydrochloride) Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CORTICOSTEROIDS NOS (View Corticosteroids Nos Review and Corticosteroids Nos Label ). Patient was hospitalized.

4674038-3 | Myelodysplastic Syndrome
on May 10, 2005 Female patient from , 77 years of age, was diagnosed with malignant melanoma and was treated with Oncovin (View Usage). Patient experienced the following unwanted or unexpected effects: myelodysplastic syndrome. Oncovin dosage: 1 Mg Other. During the same period patient was treated with DACARBAZINE (View Dacarbazine Review and Dacarbazine Label ), NIDRAN (NIMUSTINE HYDROCHLORIDE) (View Nidran (nimustine Hydrochloride) Review and Nidran (nimustine Hydrochloride) Label ), FERON (INTERFERON BETA) (View Feron (interferon Beta) Review and Feron (interferon Beta) Label ).

4662759-8 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Bilirubin Conjugated Increased, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Gamma-glutamyltransferase Increased, Laboratory Test Abnormal, Liver Disorder, Neutrophil Count Decreased
Patient was taking Oncovin (View Usage). Patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, bilirubin conjugated increased, blood alkaline phosphatase increased, blood bilirubin increased, gamma-glutamyltransferase increased, laboratory test abnormal, liver disorder, neutrophil count decreased on Apr 26, 2005 from Additional patient health information: Female patient , 71 years of age, weighting 136.7 lb, was diagnosed with acute lymphocytic leukaemia and. Oncovin dosage: 1.4 Mg Other. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DAUNORUBICIN HYDROCHLORIDE (View Daunorubicin Hydrochloride Review and Daunorubicin Hydrochloride Label ), LEUNASE (ASPARAGINASE) (View Leunase (asparaginase) Review and Leunase (asparaginase) Label ), FAMOTIDINE (View Famotidine Review and Famotidine Label ), FIRSTCIN (CEFOZOPRAN HYDROCHLORIDE) (View Firstcin (cefozopran Hydrochloride) Review and Firstcin (cefozopran Hydrochloride) Label ), ISEPACIN (ISEPAMICIN SULFATE) (View Isepacin (isepamicin Sulfate) Review and Isepacin (isepamicin Sulfate) Label ), FOY (GABEXATE MESILATE) (View Foy (gabexate Mesilate) Review and Foy (gabexate Mesilate) Label ), KYTRIL (GRINESTRON) (View Kytril (grinestron) Review and Kytril (grinestron) Label ).

4655888-6 | Antimitochondrial Antibody Positive, Biliary Cirrhosis Primary, Blood Copper Increased, Blood Immunoglobulin A Increased, Blood Immunoglobulin M Increased, Hepatitis Chronic Active, Hepatocellular Damage, Hyaluronic Acid Increased, Normochromic Normocytic Anaemia
Adverse event was reported on Apr 19, 2005 by a Male patient taking Oncovin (View Usage) (Dosage: ) was diagnosed with central nervous system lymphoma and. Location: , 56 years of age, After Oncovin was administered, patient had the following side effects: antimitochondrial antibody positive, biliary cirrhosis primary, blood copper increased, blood immunoglobulin a increased, blood immunoglobulin m increased, hepatitis chronic active, hepatocellular damage, hyaluronic acid increased, normochromic normocytic anaemia. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), CARMUSTINE (View Carmustine Review and Carmustine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), MANIDIPINE HYDROCHLORIDE (View Manidipine Hydrochloride Review and Manidipine Hydrochloride Label ). Patient was hospitalized.

4649849-0 | Back Pain, Blood Pressure Increased, Blood Pressure Systolic Decreased, Cardiac Arrest, Cardiac Failure Acute, Cardiomegaly, Depressed Level Of Consciousness, Disseminated Intravascular Coagulation
on Apr 11, 2005 Male patient from , 59 years of age, weighting 149.9 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Oncovin (View Usage). Patient experienced the following unwanted or unexpected effects: back pain (What is back pain?), blood pressure increased, blood pressure systolic decreased, cardiac arrest (What is cardiac arrest?), cardiac failure acute, cardiomegaly, depressed level of consciousness, disseminated intravascular coagulation. Oncovin dosage: 0.4 Mg Other. During the same period patient was treated with ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), DECADRON (DEXAMETHASONE DODIUM PHOSPHATE) (View Decadron (dexamethasone Dodium Phosphate) Review and Decadron (dexamethasone Dodium Phosphate) Label ).

4649843-X | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Bilirubin Conjugated Increased, Blood Albumin Decreased, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Blood Cholinesterase Decreased, Blood Fibrinogen Decreased, Condition Aggravated
on Apr 08, 2005 Female patient from , 17 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Oncovin (View Usage). Patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, bilirubin conjugated increased, blood albumin decreased, blood alkaline phosphatase increased, blood bilirubin increased, blood cholinesterase decreased, blood fibrinogen decreased, condition aggravated. Oncovin dosage: 1.3 Mg/m2 Other. During the same period patient was treated with DAUNORUBICIN (View Daunorubicin Review and Daunorubicin Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), LEUNASE (ASPARAGINASE) (View Leunase (asparaginase) Review and Leunase (asparaginase) Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

4648737-3 | Atrial Fibrillation, Influenza, Pneumonitis, Ventricular Extrasystoles
Patient was taking Oncovin (View Usage). After Oncovin was administered, patient had the following side effects: atrial fibrillation (What is atrial fibrillation?), influenza, pneumonitis, ventricular extrasystoles on Apr 08, 2005 from Additional patient health information: Male patient , 32 years of age, weighting 187.4 lb, was diagnosed with primary mediastinal large b-cell lymphoma stage iv and. Oncovin dosage: 2 Mg'; Other. During the same period patient was treated with RITUXAN (View Rituxan Review and Rituxan Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

4648372-7 | Amnesia, Brain Neoplasm, Central Nervous System Lymphoma, Dementia, Memory Impairment, Metastases To Breast, Neoplasm Recurrence, Non-hodgkin's Lymphoma Recurrent, Vitreous Disorder
Adverse event was reported on Apr 12, 2005 by a Female patient taking Oncovin (View Usage) (Dosage: 1.5 Mg/m2 Other) was diagnosed with non-hodgkin's lymphoma and. Location: , 53 years of age, Patient experienced the following unwanted or unexpected effects: amnesia, brain neoplasm, central nervous system lymphoma, dementia (What is dementia?), memory impairment, metastases to breast, neoplasm recurrence, non-hodgkin's lymphoma recurrent, vitreous disorder. During the same period patient was treated with METHOTREXATE (View Methotrexate Review and Methotrexate Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

4648346-6 | Liver Disorder
on Apr 07, 2005 Female patient from , 71 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Oncovin (View Usage). Patient had the following side effects: liver disorder. Oncovin dosage: 1.4 Mg Other. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DAUNORUBICIN HYDROCHLORIDE (View Daunorubicin Hydrochloride Review and Daunorubicin Hydrochloride Label ), LEUNASE (ASPARAGINASE) (View Leunase (asparaginase) Review and Leunase (asparaginase) Label ), GRAN (FILGRASTIM) (View Gran (filgrastim) Review and Gran (filgrastim) Label ).

4629668-1 | Atrial Fibrillation, Chest Pain, Influenza, Pneumonitis, Ventricular Extrasystoles
on Mar 17, 2005 Male patient from , 32 years of age, weighting 187.4 lb, was diagnosed with primary mediastinal large b-cell lymphoma stage iv and was treated with Oncovin (View Usage). After Oncovin was administered, patient had the following side effects: atrial fibrillation (What is atrial fibrillation?), chest pain (What is chest pain?), influenza, pneumonitis, ventricular extrasystoles. Oncovin dosage: 2 Mg Other. During the same period patient was treated with RITUXAN (View Rituxan Review and Rituxan Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

4620262-5 | Pneumonitis
Patient was taking Oncovin (View Usage). Patient experienced the following unwanted or unexpected effects: pneumonitis on Mar 03, 2005 from Additional patient health information: Male patient , 68 years of age, was diagnosed with non-hodgkin's lymphoma and. Oncovin dosage: 1mg Other. During the same period patient was treated with RITUXAN (RITUXIBAM) (View Rituxan (rituxibam) Review and Rituxan (rituxibam) Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

4620259-5 | Hbv Dna Increased, Hepatic Atrophy, Hepatic Failure, Hepatitis Fulminant, Hepatomegaly, Pneumonia Fungal
Adverse event was reported on Mar 09, 2005 by a Female patient taking Oncovin (View Usage) (Dosage: ) was diagnosed with lymphoma (What is lymphoma?) and. Location: , 60 years of age, Patient had the following side effects: hbv dna increased, hepatic atrophy, hepatic failure, hepatitis fulminant, hepatomegaly, pneumonia fungal. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HYDROCHLORIDE (View Doxorubicin Hydrochloride Review and Doxorubicin Hydrochloride Label ). Patient was hospitalized.

4620255-8 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Albumin Decreased, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Blood Cholinesterase Decreased, Blood Fibrinogen Decreased, Gamma-glutamyltransferase Increased, Hepatic Function Abnormal
on Mar 09, 2005 Female patient from , 17 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Oncovin (View Usage). After Oncovin was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood albumin decreased, blood alkaline phosphatase increased, blood bilirubin increased, blood cholinesterase decreased, blood fibrinogen decreased, gamma-glutamyltransferase increased, hepatic function abnormal. Oncovin dosage: 1.3 Mg/m2 Other. During the same period patient was treated with DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ELSPAR (View Elspar Review and Elspar Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

4618397-6 | Back Pain, Bacterial Infection, Blood Pressure Increased, Cardiac Arrest, Cardiac Failure Acute, Cardiomegaly, Depressed Level Of Consciousness, Disseminated Intravascular Coagulation
on Mar 02, 2005 Male patient from , 59 years of age, weighting 149.9 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Oncovin (View Usage). Patient experienced the following unwanted or unexpected effects: back pain (What is back pain?), bacterial infection (What is bacterial infection?), blood pressure increased, cardiac arrest (What is cardiac arrest?), cardiac failure acute, cardiomegaly, depressed level of consciousness, disseminated intravascular coagulation. Oncovin dosage: 0.4 Mg Other. During the same period patient was treated with ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), DECADRON (DEXAMETHASONE SODIUM PHOSHATE) (View Decadron (dexamethasone Sodium Phoshate) Review and Decadron (dexamethasone Sodium Phoshate) Label ).

4618392-7 | Cytomegalovirus Test Positive, Disease Recurrence, Hepatitis Viral, Herpes Simplex Serology Positive, Immunosuppression, Varicella
Patient was taking Oncovin (View Usage). Patient had the following side effects: cytomegalovirus test positive, disease recurrence, hepatitis viral, herpes simplex serology positive, immunosuppression, varicella on Mar 08, 2005 from Additional patient health information: Female patient , 36 years of age, weighting 116.8 lb, was diagnosed with diffuse large b-cell lymphoma stage ii and. Oncovin dosage: 2 Mg Other. During the same period patient was treated with METHOTREXATE (View Methotrexate Review and Methotrexate Label ), ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), BLEOMYCIN (View Bleomycin Review and Bleomycin Label ), KYTRIL (View Kytril Review and Kytril Label ). Patient was hospitalized.

4613270-1 | Cardiac Failure Congestive, Febrile Neutropenia, Red Blood Cell Count Decreased
Adverse event was reported on Feb 25, 2005 by a Female patient taking Oncovin (View Usage) (Dosage: ) was diagnosed with non-hodgkin's lymphoma and. Location: , 65 years of age, After Oncovin was administered, patient had the following side effects: cardiac failure congestive, febrile neutropenia, red blood cell count decreased. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), GRANULOCYTE COLONY STIMULATING FACTOR (View Granulocyte Colony Stimulating Factor Review and Granulocyte Colony Stimulating Factor Label ).

4613269-5 | Cystitis Haemorrhagic, Febrile Neutropenia, Platelet Count Decreased, Red Blood Cell Count Decreased
on Feb 25, 2005 Female patient from , 65 years of age, was diagnosed with non-hodgkin's lymphoma and was treated with Oncovin (View Usage). Patient experienced the following unwanted or unexpected effects: cystitis haemorrhagic, febrile neutropenia, platelet count decreased, red blood cell count decreased. Oncovin dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), GRANULOCYTE COLONY STIMULATING FACTOR (View Granulocyte Colony Stimulating Factor Review and Granulocyte Colony Stimulating Factor Label ).

4613260-9 | Back Pain, Blood Culture Positive, Blood Pressure Increased, Cardiac Arrest, Cardiac Failure Acute, Cardiomegaly, Depressed Level Of Consciousness, Disseminated Intravascular Coagulation
on Mar 02, 2005 Male patient from , 59 years of age, weighting 149.9 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Oncovin (View Usage). Patient had the following side effects: back pain (What is back pain?), blood culture positive, blood pressure increased, cardiac arrest (What is cardiac arrest?), cardiac failure acute, cardiomegaly, depressed level of consciousness, disseminated intravascular coagulation. Oncovin dosage: 0.4 Mg Other. During the same period patient was treated with ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), DECADRON (View Decadron Review and Decadron Label ).

4608423-2 | Confusional State
Patient was taking Oncovin (View Usage). After Oncovin was administered, patient had the following side effects: confusional state on Feb 18, 2005 from Additional patient health information: Female patient , 50 years of age, . Oncovin dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

4607243-2 | Alpha Tumour Necrosis Factor Increased, Blood Creatinine Increased, Blood Urea Increased, Condition Aggravated, Haemodialysis, Hyperkalaemia, Hyperuricaemia, Interleukin Level Increased, Laboratory Test Abnormal
Adverse event was reported on Feb 22, 2005 by a Male patient taking Oncovin (View Usage) (Dosage: 2 Mg) . Location: , 27 years of age, Patient experienced the following unwanted or unexpected effects: alpha tumour necrosis factor increased, blood creatinine increased, blood urea increased, condition aggravated, haemodialysis, hyperkalaemia, hyperuricaemia, interleukin level increased, laboratory test abnormal. During the same period patient was treated with PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

4599892-5 | Bacterial Infection, Bronchopulmonary Aspergillosis, Cardiovascular Disorder, Stem Cell Transplant, White Blood Cell Count Decreased
on Feb 15, 2005 Female patient from , 52 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Oncovin (View Usage). Patient had the following side effects: bacterial infection (What is bacterial infection?), bronchopulmonary aspergillosis, cardiovascular disorder, stem cell transplant, white blood cell count decreased. Oncovin dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DAUNORUBICIN HYDROCHLORIDE (View Daunorubicin Hydrochloride Review and Daunorubicin Hydrochloride Label ). Patient was hospitalized.

4599890-1 | Cardiac Failure Acute, Pneumonitis, Respiratory Failure
on Feb 16, 2005 Male patient from , 57 years of age, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Oncovin (View Usage). After Oncovin was administered, patient had the following side effects: cardiac failure acute, pneumonitis, respiratory failure. Oncovin dosage: 0.4 Mg Other. During the same period patient was treated with ADRIACIN (DOXORUBICIN HYDROCHLORIDE) (View Adriacin (doxorubicin Hydrochloride) Review and Adriacin (doxorubicin Hydrochloride) Label ), DECADRON (View Decadron Review and Decadron Label ).

4588436-X | Neuropathy, Peripheral Vascular Disorder
Patient was taking Oncovin (View Usage). Patient experienced the following unwanted or unexpected effects: neuropathy, peripheral vascular disorder on Feb 01, 2005 from Additional patient health information: Male patient , 73 years of age, weighting 180.8 lb, was diagnosed with mantle cell lymphoma and. Oncovin dosage: 2 Mg. During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), RITUXAN (View Rituxan Review and Rituxan Label ).

4588103-2 | Acute Myeloid Leukaemia, Pneumonia
Adverse event was reported on Feb 02, 2005 by a Female patient taking Oncovin (View Usage) (Dosage: 2 Mg Other) was diagnosed with acute lymphocytic leukaemia and. Location: , 62 years of age, weighting 116.8 lb, Patient had the following side effects: acute myeloid leukaemia, pneumonia (What is pneumonia?). During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DAUNOMYCIN (View Daunomycin Review and Daunomycin Label ), LEUNASE (ASPARAGINASE) (View Leunase (asparaginase) Review and Leunase (asparaginase) Label ), ADRIACIAN (DOXORUBICIN HYDROCHLORIDE) (View Adriacian (doxorubicin Hydrochloride) Review and Adriacian (doxorubicin Hydrochloride) Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), VEPESID (View Vepesid Review and Vepesid Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ).

4588102-0 | Abscess, Bone Marrow Depression, Diaphragmatic Disorder, Lung Abscess, Multi-organ Failure, Psoas Abscess, Pulmonary Congestion, Sepsis
on Feb 02, 2005 Male patient from , child 12 years of age, weighting 121.3 lb, was diagnosed with abdominal neoplasm and was treated with Oncovin (View Usage). After Oncovin was administered, patient had the following side effects: abscess (What is abscess?), bone marrow depression, diaphragmatic disorder, lung abscess, multi-organ failure, psoas abscess, pulmonary congestion, sepsis (What is sepsis?). Oncovin dosage: 2 Mg Other. During the same period patient was treated with PINORUBIN (PIRABURICIN) (View Pinorubin (piraburicin) Review and Pinorubin (piraburicin) Label ), COSMEGEN (View Cosmegen Review and Cosmegen Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), IFOMIDE (IFOSFAMIDE) (View Ifomide (ifosfamide) Review and Ifomide (ifosfamide) Label ).

4588099-3 | Chest Pain, Dyspnoea, Lung Infiltration, Platelet Count Decreased, Pulmonary Haemorrhage
on Jan 28, 2005 Male patient from , 32 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Oncovin (View Usage). Patient experienced the following unwanted or unexpected effects: chest pain (What is chest pain?), dyspnoea, lung infiltration, platelet count decreased, pulmonary haemorrhage. Oncovin dosage: 1.3 Mg/m2 Other. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), IMATINIB (View Imatinib Review and Imatinib Label ), PREDNISOLONE SODIUM SUCCINATE INJ (View Prednisolone Sodium Succinate Inj Review and Prednisolone Sodium Succinate Inj Label ).

4588085-3 | Abdominal Distension, Condition Aggravated, Constipation, Ileus Paralytic, Tumour Lysis Syndrome
Patient was taking Oncovin (View Usage). Patient had the following side effects: abdominal distension, condition aggravated, constipation (What is constipation?), ileus paralytic, tumour lysis syndrome on Feb 01, 2005 from Additional patient health information: Male patient , 75 years of age, weighting 94.80 lb, was diagnosed with diffuse large b-cell lymphoma and. Oncovin dosage: 1.97 Mg Other. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ............ (View ............ Review and ............ Label ), ADRIACIN (DOXORUBICIN HYDROCHLORIDE) (View Adriacin (doxorubicin Hydrochloride) Review and Adriacin (doxorubicin Hydrochloride) Label ), DECADRON (View Decadron Review and Decadron Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ).

4572084-1 | Neuropathy Peripheral
Adverse event was reported on Jan 11, 2005 by a Male patient taking Oncovin (View Usage) (Dosage: ) was diagnosed with lymphoma (What is lymphoma?) and. Location: , 74 years of age, After Oncovin was administered, patient had the following side effects: neuropathy peripheral. During the same period patient was treated with DOXYCYCLINE (View Doxycycline Review and Doxycycline Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), RITUXAN (View Rituxan Review and Rituxan Label ).

4571161-9 | Blood Creatinine Increased, Constipation, Foetal Cardiac Disorder, Ileus Paralytic, Oral Intake Reduced, Tumour Lysis Syndrome, Urine Output Decreased, Weight Increased
on Jan 19, 2005 Male patient from , 72 years of age, was diagnosed with diffuse large b-cell lymphoma and was treated with Oncovin (View Usage). Patient experienced the following unwanted or unexpected effects: blood creatinine increased, constipation (What is constipation?), foetal cardiac disorder, ileus paralytic, oral intake reduced, tumour lysis syndrome, urine output decreased, weight increased. Oncovin dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ). Patient was hospitalized.

4564684-X | Acute Myocardial Infarction, Coronary Artery Occlusion
on Dec 28, 2004 Male patient from , 69 years of age, weighting 167.6 lb, was diagnosed with malignant melanoma and was treated with Oncovin (View Usage). Patient had the following side effects: acute myocardial infarction, coronary artery occlusion. Oncovin dosage: 1 Mg Other. During the same period patient was treated with FERON (INTERFERON BETA) (View Feron (interferon Beta) Review and Feron (interferon Beta) Label ), DACARBAZINE (View Dacarbazine Review and Dacarbazine Label ), KYTRIL (View Kytril Review and Kytril Label ). Patient was hospitalized.

4564677-2 | Abnormal Chest Sound, Acute Respiratory Distress Syndrome, Dyspnoea, Hypoxia, Infection, Platelet Count Decreased, Pneumonitis, Pyrexia, Stem Cell Transplant
Patient was taking Oncovin (View Usage). After Oncovin was administered, patient had the following side effects: abnormal chest sound, acute respiratory distress syndrome, dyspnoea, hypoxia, infection (What is infection?), platelet count decreased, pneumonitis, pyrexia, stem cell transplant on Jan 05, 2005 from Additional patient health information: Male patient , child 8 years of age, was diagnosed with brain neoplasm and. Oncovin dosage: 1.3 Mg Day. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), RANDA (CISPLATIN PHARMACIA) (View Randa (cisplatin Pharmacia) Review and Randa (cisplatin Pharmacia) Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), ZOFRAN (View Zofran Review and Zofran Label ), MESNA (View Mesna Review and Mesna Label ).

4562951-7 | Cholestasis
Adverse event was reported on Dec 27, 2004 by a Male patient taking Oncovin (View Usage) (Dosage: 1.6 Mg Other) was diagnosed with lymphoma (What is lymphoma?) and. Location: , 66 years of age, weighting 112.4 lb, Patient experienced the following unwanted or unexpected effects: cholestasis. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ADRIACIN (DOXORUBICIN HYDROCHLORIDE) (View Adriacin (doxorubicin Hydrochloride) Review and Adriacin (doxorubicin Hydrochloride) Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

4553450-7 | Binocular Eye Movement Disorder, Clonus, Depressed Level Of Consciousness, Inappropriate Antidiuretic Hormone Secretion, Reversible Posterior Leukoencephalopathy Syndrome
on Dec 22, 2004 Male patient from , child 6 years of age, was diagnosed with non-hodgkin's lymphoma stage iii and was treated with Oncovin (View Usage). Patient had the following side effects: binocular eye movement disorder, clonus, depressed level of consciousness, inappropriate antidiuretic hormone secretion, reversible posterior leukoencephalopathy syndrome. Oncovin dosage: . During the same period patient was treated with DANORUBICIN HYDROCHLORIDE (View Danorubicin Hydrochloride Review and Danorubicin Hydrochloride Label ). Patient was hospitalized.

4553448-9 | Condition Aggravated, Convulsion, Endocrine Disorder, Hypertension, Hypertensive Encephalopathy, Neuroblastoma, Reversible Posterior Leukoencephalopathy Syndrome
on Dec 22, 2004 Male patient from , child 4 years of age, was diagnosed with neuroblastoma (What is neuroblastoma?) and was treated with Oncovin (View Usage). After Oncovin was administered, patient had the following side effects: condition aggravated, convulsion, endocrine disorder, hypertension, hypertensive encephalopathy, neuroblastoma (What is neuroblastoma?), reversible posterior leukoencephalopathy syndrome. Oncovin dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), PIRARUBICIN (View Pirarubicin Review and Pirarubicin Label ). Patient was hospitalized.

4546892-7 | Abdominal Pain, Aspartate Aminotransferase Increased, Bacillus Infection, Blood Culture Positive, Blood Lactate Dehydrogenase Increased, Blood Pressure Inadequately Controlled, Coma, Dyspnoea, Granulocyte Count Decreased
Patient was taking Oncovin (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), aspartate aminotransferase increased, bacillus infection, blood culture positive, blood lactate dehydrogenase increased, blood pressure inadequately controlled, coma, dyspnoea, granulocyte count decreased on Dec 15, 2004 from Additional patient health information: Male patient , child 3 years of age, was diagnosed with acute lymphocytic leukaemia and. Oncovin dosage: . During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

4546882-4 | Acute Myocardial Infarction
Adverse event was reported on Dec 16, 2004 by a Male patient taking Oncovin (View Usage) (Dosage: ) was diagnosed with malignant melanoma and. Location: , 69 years of age, Patient had the following side effects: acute myocardial infarction.

4546585-6 | Abdominal Pain, Bacillus Infection, Bacterial Sepsis, Blood Amylase Increased, Blood Pressure Decreased, Coma, Depressed Level Of Consciousness, Dyspnoea, Granulocyte Count Decreased
on Dec 15, 2004 Male patient from , child 3 years of age, was treated with Oncovin (View Usage). After Oncovin was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), bacillus infection, bacterial sepsis, blood amylase increased, blood pressure decreased, coma, depressed level of consciousness, dyspnoea, granulocyte count decreased. Oncovin dosage: . During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.